洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展 Does the minimally invasive direct anterior approach result in less postoperative muscle damage and a faster functional recovery trajectory compared with the minimally invasive direct lateral approach in patients undergoing primary uncemented total hip arthroplasty?

【ChiCTR2600121733】Does the minimally invasive direct anterior approach result in less postoperative muscle damage and a faster functional recovery trajectory compared with the minimally invasive direct lateral approach in patients undergoing primary uncemented total hip arthroplasty?

查看原文
立即下载
基本信息
登记号

ChiCTR2600121733

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-04-02

临床申请受理号

/

靶点

/

适应症

Hip osteoarthritis

试验通俗题目

Does the minimally invasive direct anterior approach result in less postoperative muscle damage and a faster functional recovery trajectory compared with the minimally invasive direct lateral approach in patients undergoing primary uncemented total hip arthroplasty?

试验专业题目

At MRI, the minimally invasive direct anterior approach produces less muscle alterations compared to the minimally invasive direct lateral approach in uncemented total hip arthroplasty: a prospective quasi-randomized study

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The primary objective of this study is to compare postoperative muscle alterations between the minimally invasive direct anterior approach (DAA) and the minimally invasive direct lateral approach (DLA) in patients undergoing primary uncemented total hip arthroplasty, as assessed by magnetic resonance imaging at 12 months. Secondary objectives are to compare the trajectory of functional recovery and health-related quality of life between the two surgical approaches at 1, 3, 6, and 12 months postoperatively.

试验分类
请登录查看
试验类型

非随机对照试验

试验分期

其它

随机化

This is a prospective quasi-randomized study. Allocation was determined according to predefined operative scheduling days. No computer-generated random sequence was used.

盲法

None.

试验项目经费来源

This study received no external funding.

试验范围

/

目标入组人数

21;19

实际入组人数

/

第一例入组时间

2022-01-05

试验终止时间

2024-01-10

是否属于一致性

/

入选标准

1. Adult patients undergoing primary THA for hip osteoarthritis 2. Eligibility for uncemented THA 3. Ability to complete clinical follow-up 4. Eligibility for MRI examination at 12 months；

排除标准

1. Hip fracture or post-traumatic arthritis 2. Inflammatory or autoimmune joint disease 3. Neuromuscular disorders 4. Active malignancy or chronic immunosuppression 5. Contraindications to MRI；

研究者信息
研究负责人姓名
请登录查看
试验机构

Department of Orthopaedics and Traumatology, Sant’Andrea University Hospital, Sapienza University of Rome

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Department of Orthopaedics and Traumatology, Sant’Andrea University Hospital, Sapienza University of Rome的其他临床试验

更多

Sant’Andrea University Hospital的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品